The clinical development of a 5 alpha-reductase inhibitor, finasteride.
💡 한 문장 핵심
5알파환원효소 억제제 finasteride의 임상 개발.
4/5 보강
TL;DR
Selective inhibition of 5 alpha-reductase by finasteride may provide a novel approach to BPH therapy by reducing prostate size without affecting T-dependent processes such as fertility, muscle strength, and libido.
📑 코퍼스 인용 관계
· 인용됨 12
📑 인용한 논문 (6) ▾
- Clomiphene citrate rescue of spermatogenesis in men with infertility while remaining on fi… Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2017
- Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride… PeerJ · 2017
- Association between variants in genes involved in the immune response and prostate cancer … The Prostate · 2017
- Experimental, molecular docking investigations and bioavailability study on the inclusion … Drug design, development and therapy · 2017
- Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know? Reviews in endocrine & metabolic disorders · 2015
- Finasteride and Male Breast Cancer: Does the MHRA Report Show a Link? Journal of cutaneous and aesthetic surgery · 2010
연도별 인용 (2012–2026) · 합계 42
OpenAlex 토픽 ·
Hormonal and reproductive studies
Sexual Differentiation and Disorders
Urinary Bladder and Prostate Research
Abstract 🌐 Abstract
Finasteride, a 4-aza steroid compound, is an orally active inhibitor of the 5 alpha-reductase enzyme. 5 alpha-Reductase is necessary for the metabolism of testosterone (T) to dihydrotestosterone (DHT) and is found in high levels only in certain tissues such as the prostate. Finasteride has been shown to markedly suppress serum DHT levels in man without lowering testosterone levels. In patients with benign prostate hyperplasia (BPH), finasteride was found to decrease prostate volume by a mean of 28% over a period of 6 months, without causing clinically significant adverse effects. DHT appears to be the primary androgen for prostatic growth. Selective inhibition of 5 alpha-reductase by finasteride may provide a novel approach to BPH therapy by reducing prostate size without affecting T-dependent processes such as fertility, muscle strength, and libido. The clinical development of finasteride for the treatment of benign prostate hyperplasia is reviewed.
Selective inhibition of 5 alpha-reductase by finasteride may provide a novel approach to BPH therapy by reducing prostate size without affecting T-dependent processes such as fertility, muscle strengt
APA 7
Stoner, E. (1990). The clinical development of a 5 alpha-reductase inhibitor, finasteride.. The Journal of steroid biochemistry and molecular biology, 37(3), 375-8. https://doi.org/10.1016/0960-0760(90)90487-6
Vancouver
Stoner E. The clinical development of a 5 alpha-reductase inhibitor, finasteride. Jour. ster. bioc. mole. biol.. 1990;37(3):375-8. doi:10.1016/0960-0760(90)90487-6
AMA 11
Stoner E. The clinical development of a 5 alpha-reductase inhibitor, finasteride. Jour. ster. bioc. mole. biol.. 1990;37(3):375-8. doi:10.1016/0960-0760(90)90487-6
Chicago
Stoner, E.. 1990. "The clinical development of a 5 alpha-reductase inhibitor, finasteride." The Journal of steroid biochemistry and molecular biology 37 (3): 375-8. https://doi.org/10.1016/0960-0760(90)90487-6
MLA 9
Stoner, E.. "The clinical development of a 5 alpha-reductase inhibitor, finasteride." The Journal of steroid biochemistry and molecular biology, vol. 37, no. 3, 1990, pp. 375-8. doi:10.1016/0960-0760(90)90487-6.
PMID
1701660 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 5/8 (63%)
· 참조 0편 · 후속 5편
이 논문을 인용한 후속 연구 12
- Finasteride: a review of its use in male pattern hair loss.
- Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
- A new look at the 5alpha-reductase inhibitor finasteride.
- Clinical pharmacokinetics and pharmacodynamics of finasteride.
- Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutas…
- Inhibition of human steroid 5beta-reductase (AKR1D1) by finasteride and structure of the enzyme-inhi…
- Finasteride and Male Breast Cancer: Does the MHRA Report Show a Link?
- Finasteride-its impact on sexual function and prostate cancer.
- Experimental, molecular docking investigations and bioavailability study on the inclusion complexes …
- Association between variants in genes involved in the immune response and prostate cancer risk in me…
- Clomiphene citrate rescue of spermatogenesis in men with infertility while remaining on finasteride:…
- A risk-benefit assessment of pharmacological therapies for hirsutism.
같은 제1저자의 인용 많은 논문 (5)
- Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia.
- The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group.
- Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.
- Clinical experience of the detection of prostate cancer in patients with benign prostate hyperplasia treated with finasteride. The Finasteride Study Group.
- 5alpha-reductase inhibitors/finasteride.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- 피나스테리드가 전립선암 발생에 미치는 영향.
- 양성 전립선 비대증의 임상적 진행에 대한 doxazosin, finasteride 및 병용 요법의 장기 효과.
- 양성 전립선 비대증 환자에서 finasteride의 효과. The Finasteride Study Group.
- 양성 전립선 비대증 남성에서 급성 요폐의 위험과 수술적 치료 필요성에 대한 finasteride의 효과. Finasteride Long-Term Efficacy and Safety Study Group.
- 양성 전립선 비대증 남성에서 finasteride의 효과.
- 이중 5alpha-reductase 억제제인 dutasteride에 의한 양성전립선비대증 남성에서의 dihydrotestosterone의 현저한 억제.